Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Restaurant
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
Ozempic
Wegovy |
| gptkbp:chemicalFormula |
C187H265N43O51S
|
| gptkbp:clinicalTrials |
promotes weight loss
NCT02990843 NCT03108133 improves cardiovascular outcomes reduces HbA1c levels |
| gptkbp:contraindication |
multiple endocrine neoplasia syndrome type 2
personal or family history of medullary thyroid carcinoma |
| gptkbp:developedBy |
Novo Nordisk
|
| gptkbp:dosageForm |
vial
pre-filled pen |
| gptkbp:drugInterdiction |
subcutaneous absorption
protein binding excretion primarily in urine metabolism by proteolytic enzymes |
| gptkbp:endOfLife |
about 1 week
|
| gptkbp:formulation |
injectable solution
|
| gptkbp:hasPopulation |
adults with obesity
adults with type 2 diabetes |
| gptkbp:healthcare |
self-administration
once weekly dosing |
| https://www.w3.org/2000/01/rdf-schema#label |
Semaglutide
|
| gptkbp:impact |
long-term use recommended
|
| gptkbp:interactsWith |
may interact with insulin
may interact with other antidiabetic medications |
| gptkbp:is_monitored_by |
renal function
weight changes blood glucose levels |
| gptkbp:issuedBy |
subcutaneous injection
|
| gptkbp:lastProduced |
2017
|
| gptkbp:mandates |
improving glycemic control
chronic weight management |
| gptkbp:marketedAs |
antidiabetic agent
anti-obesity medication |
| gptkbp:researchAreas |
metabolic syndrome
non-alcoholic fatty liver disease obesity treatment cardiovascular risk reduction |
| gptkbp:resources |
gptkb:American_Diabetes_Association
gptkb:European_Association_for_the_Study_of_Diabetes |
| gptkbp:route |
subcutaneous
|
| gptkbp:sideEffect |
nausea
abdominal pain vomiting diarrhea constipation |
| gptkbp:storage |
refrigerated
protected from light |
| gptkbp:triggerType |
stimulates insulin secretion
inhibits glucagon secretion |
| gptkbp:usedFor |
weight management
type 2 diabetes management |
| gptkbp:weight |
4113.6 g/mol
|